Olutasidenib
![]() | |
Names | |
---|---|
Trade names | Rezlidhia |
Other names | FT-2102 |
Clinical data | |
Drug class | IDH1 inhibitor[1] |
Main uses | Acute myeloid leukemia[1] |
Side effects | Nausea, tiredness, joint pain, constipation, shortness of breath, fever, rash, inflammation of the mouth, diarrhea[1] |
Routes of use | By mouth |
Typical dose | 150 mg BID[1] |
External links | |
AHFS/Drugs.com | Monograph |
Legal | |
License data |
|
Legal status | |
Chemical and physical data | |
Formula | C18H15ClN4O2 |
Molar mass | 354.79 g·mol−1 |
3D model (JSmol) | |
| |
|
Olutasidenib, sold under the brand name Rezlidhia, is an medication used to treat acute myeloid leukemia.[1] Specifically it is used in those with certain IDH1 mutations who have failed other treatments.[1] It is taken by mouth.[1]
Common side effects include nausea, tiredness, joint pain, constipation, shortness of breath, fever, rash, inflammation of the mouth, and diarrhea.[1] Common lab abnormalities include high potassium, low sodium, liver problems, and kidney problems.[1] Other side effects may include differentiation syndrome.[1] It is an isocitrate dehydrogenase-1 (IDH1) inhibitor.[1]
Olutasidenib was approved for medical use in the United States in 2022.[1] In the United States it costs about 32,200 USD per month as of 2022.[4]
Medical uses
Olutasidenib is indicated for the treatment of adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.[2][3][5]
Dosage
It is taken at a dose of 150 mg twice per day.[1]
Society and culture
Names
Olutasidenib is the international nonproprietary name.[6]
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 "REZLIDHIA™ (olutasidenib) capsules, for oral use". Archived from the original on 15 January 2023. Retrieved 15 January 2023.
- ↑ 2.0 2.1 "Archive copy" (PDF). Archived (PDF) from the original on 2022-12-13. Retrieved 2022-12-20.
{{cite web}}
: CS1 maint: archived copy as title (link) - ↑ 3.0 3.1 https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215814Orig1s000ltr.pdf Archived 2022-12-20 at the Wayback Machine
This article incorporates text from this source, which is in the public domain.
- ↑ "Optum Rx Revenue Grows 9% in 2022". Formulary Watch. Archived from the original on 15 January 2023. Retrieved 15 January 2023.
- ↑ "FDA approves olutasidenib". U.S. Food and Drug Administration (FDA). 1 December 2022. Archived from the original on 20 December 2022. Retrieved 20 December 2022.
- ↑ World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information. 33 (3). hdl:10665/330879.
External links
External sites: | |
---|---|
Identifiers: |
|
- Liu X, Gong Y (2019). "Isocitrate dehydrogenase inhibitors in acute myeloid leukemia". Biomarker Research. 7: 22. doi:10.1186/s40364-019-0173-z. PMC 6806510. PMID 31660152.
- Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, et al. (November 2022). "Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial". The Lancet Haematology. doi:10.1016/S2352-3026(22)00292-7. PMID 36370742. S2CID 253471380.
- Clinical trial number NCT02719574 for "Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation" at ClinicalTrials.gov
- Pages using duplicate arguments in template calls
- CS1 maint: archived copy as title
- Webarchive template wayback links
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs not assigned an ATC code
- Antineoplastic drugs
- Orphan drugs
- Nitriles
- Pyridones
- Chloroarenes
- Quinolones